LONG, G. V.; HAUSCHILD, A.; SANTINAMI, M.; ATKINSON, V.; MANDALA, M.; CHIARION-SILENI, V.; LARKIN, J.; NYAKAS, M.; DUTRIAUX, C.; HAYDON, A.; ROBERT, C.; MORTIER, L.; SCHACHTER, J.; SCHADENDORF, D.; LESIMPLE, T.; PLUMMER, R.; JI, R.; ZHANG, P.; MOOKERJEE, B.; LEGOS, J.; KEFFORD, R.; DRUMMER, R.; KIRKWOOD, J. M. Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, n. S1, p. S43, 2018. DOI: 10.25251/skin.2.supp.43. Disponível em: https://www.jofskin.org/index.php/skin/article/view/291. Acesso em: 19 may. 2022.